|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Clinical Care/Education/Nutrition |
The Benefits of Metformin Therapy During Continuous Subcutaneous Insulin Infusion Treatment of Type 1 Diabetic Patients
1 Service de Diabétologie, Maladies Métaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d’Arc, Centre Hospitalo-Universitaire de Nancy, Toul, France
2 Faculty of Medicine, University of Melbourne, Melbourne, Australia
3 Faculty of Economics, University of Mons, Mons, Belgium
4 LIPHA Santé, Nogent-sur-Marne, France
OBJECTIVE—This study was designed to assess the insulin-sparing effect of oral administration of metformin along with a continuous subcutaneous insulin infusion (CSII) for the treatment of type 1 diabetic patients.
RESEARCH DESIGN AND METHODS—A total of 62 patients (25 women and 37 men) were studied in a monocenter, randomized, double-blind placebo-controlled study, comparing metformin (850 mg b.i.d.) with placebo in association with CSII during a 6-month period.
RESULTS—Treatment with metformin was associated with a reduction in daily insulin requirements between V0 and V6 of -4.3 ± 9.9 units (-7.8 ± 18%) compared with an increase with placebo treatment of 1.7 ± 8.3 units (2.8 ± 12.7%) (P = 0.0043). A decrease in basal requirement of insulin was also observed in patients treated with metformin of -2.6 ± 3.2 units (-7.9 ± 23.8%) compared with an increase with placebo treatment of 1.9 ± 5.7 units (8.8 ± 27.1%) (P = 0.023). HbA1c remained unchanged in treatment with metformin and placebo between V0 and V6. The number of hypoglycemic events (<60 mg/dl) was similar in both groups. Significant reductions of total cholesterol (P = 0.04) and LDL cholesterol (P = 0.05) were observed in patients treated with metformin. Gastrointestinal events, including diarrhea and abdominal pain, were reported in three patients in the metformin group who discontinued the trial. Mild or moderate gastrointestinal side effects were also reported in eight patients treated with metformin and two patients treated with placebo (P = 0.069).
CONCLUSIONS—Metformin was found to be a safe insulin-sparing agent, when used in combination with CSII for the treatment of type 1 diabetes.
Abbreviations: CSII, continuous subcutaneous insulin infusion • DCCT, Diabetes Control and Complications Trial • IR, insulin requirement • SMBG, self-monitoring of blood glucose
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Altschuler, S. J. Casella, T. A. MacKenzie, and K. M. Curtis The Effect of Cinnamon on A1C Among Adolescents With Type 1 Diabetes Diabetes Care, April 1, 2007; 30(4): 813 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Strowig and P. Raskin The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes Diabetes Care, July 1, 2005; 28(7): 1562 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y.Y. Cheng and I. G. Fantus Oral antihyperglycemic therapy for type 2 diabetes mellitus Can. Med. Assoc. J., January 18, 2005; 172(2): 213 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 OTHER ARTICLES NOTED (24 Jan 03 to 18 Apr 03) Evid. Based Nurs., July 1, 2003; 6(3): e1 - 12. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Faichney and P. W. Tate Metformin in Type 1 Diabetes: Is this a good or bad idea? Diabetes Care, May 1, 2003; 26(5): 1655 - 1655. [Full Text] [PDF]
|
|
|
|
|
|
L. Meyer and B. Guerci Metformin and Insulin in Type 1 Diabetes: The first step Diabetes Care, May 1, 2003; 26(5): 1655 - 1656. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |